株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

骨壊死:パイプライン分析

Osteonecrosis - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 255968
出版日 ページ情報 英文 40 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
骨壊死:パイプライン分析 Osteonecrosis - Pipeline Review, H2 2016
出版日: 2016年11月23日 ページ情報: 英文 40 Pages
概要

骨壊死は骨に対する血液の供給が不足した場合に起こる状態です。骨盤および肩の骨に最も多く、膝、肘、手首、足首といった他の大関節にも発生する場合があります。疾患、骨折や脱臼など、骨への血流に影響する外傷によって発生します。初期の段階では特に症状が出ず、対症療法が有効です。

当レポートでは、骨壊死に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

骨壊死の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究所別

パイプライン製品の概要

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究所別

治療薬の開発に従事している企業

  • Bone Therapeutics SA
  • Enzo Biochem, Inc.
  • K-Stemcell Co., Ltd.

治療薬の評価

  • 単独療法の製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

最新のパイプライン情報

開発休止中のプロジェクト

製品開発のマイルストーン

  • 注目情報とプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8699IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteonecrosis - Pipeline Review, H2 2016, provides an overview of the Osteonecrosis (Musculoskeletal Disorders) pipeline landscape.

Osteonecrosis is bone death caused by poor blood supply to the area. It is most common in the hip and shoulder, but can affect other large joints such as knee, elbow, wrist and ankle. Osteonecrosis can be caused by disease, or a severe trauma, such as a break or dislocation, that affects the blood supply to the bone. There are no symptoms in the early stages. Symptomatic treatment is available.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteonecrosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Osteonecrosis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteonecrosis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteonecrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 1 and 3 respectively.Osteonecrosis.

Osteonecrosis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteonecrosis (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Osteonecrosis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteonecrosis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteonecrosis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteonecrosis (Musculoskeletal Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteonecrosis (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteonecrosis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • List of Tables
  • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
  • Osteonecrosis Overview
  • Therapeutics Development
  • Pipeline Products for Osteonecrosis - Overview
  • Osteonecrosis - Therapeutics under Development by Companies
  • Osteonecrosis - Pipeline Products Glance
  • Late Stage Products
  • Clinical Stage Products
  • Early Stage Products
  • Osteonecrosis - Products under Development by Companies
  • Osteonecrosis - Companies Involved in Therapeutics Development
  • Bone Therapeutics SA
  • Enzo Biochem Inc
  • K-Stemcell Co Ltd
  • Osteonecrosis - Therapeutics Assessment
  • Assessment by Monotherapy Products
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Drug Profiles
  • ALLOB - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LWnt-3a - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PREOB - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Agonize LRP for Osteonecrosis Of Jaws - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Stem Cell Therapy for Musculoskeletal, CNS Disorders, Dermatology, Immunology and Cardiovascular Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Osteonecrosis - Dormant Projects
  • Osteonecrosis - Product Development Milestones
  • Featured News & Press Releases
  • Oct 05, 2016: Bone Therapeutics reports positive efficacy data for the ALLOB Phase IIA spinal fusion trial
  • Jun 08, 2016: Bone Therapeutics demonstrates superiority of PREOB in Phase IIB osteonecrosis study presented at EULAR
  • May 03, 2016: Bone Therapeutics completes recruitment of its ALLOB Phase IIA spinal fusion study
  • Dec 04, 2014: Bone Therapeutics Authorised to Enrol Patients in the UK in Pivotal Phase III Osteonecrosis Trial with PREOB
  • Nov 07, 2013: Bone Therapeutics' pivotal phase III osteonecrosis trial with PREOB hits a new milestone
  • Jan 28, 2013: Bone Therapeutics Raises €1.6m In Grant Subsidies From SRIW And Sambrinvest For Autologous Bone Cell Therapy
  • Oct 15, 2012: Bone Therapeutics Receives Clearance For Pivotal Phase III Osteonecrosis Trial With Preob In Europe And Treats The First Patients In Study
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Osteonecrosis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Osteonecrosis - Pipeline by Bone Therapeutics SA, H2 2016
  • Osteonecrosis - Pipeline by Enzo Biochem Inc, H2 2016
  • Osteonecrosis - Pipeline by K-Stemcell Co Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Osteonecrosis - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Osteonecrosis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top